Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice – Results of the Non-Interventional DETECT Study

References

• AbholzH, GillissenA, MagnussenH, et al. Nationale versorgungsleitlinie COPD [National Disease Management Guideline COPD]. German. 2012 Available from: http://www.versorgungsleitlinien.de. Accessed 822, 2019.
   Google Scholar
• The Global Strategy for the Diagnosis, Management and Prevention of COPD. Global initiative for chronic obstructive lung disease. GOLD. 2019 Available from: http://www.goldcopd.org. Accessed 822, 2019.
   Google Scholar
• Soler-CataluñaJJ, Martínez-GarcíaMA, Román SánchezP, SalcedoE, NavarroM, OchandoR. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925–931. doi:10.1136/thx.2005.04052716055622
   PubMed Web of Science ®Google Scholar
• World Health Organization; ebrary, Inc. World Health Statistics 2008. Geneva, Switzerland: World Health Organization;; 2008:110 ISBN: 978 92 4 0682740 Available from: https://www.who.int/gho/publications/world_health_statistics/EN_WHS08_Full.pdf. Accessed 822, 2019.
   Google Scholar
• VestboJ, HurdSS, AgustíAG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–365. doi:10.1164/rccm.201204-0596PP22878278
   PubMed Web of Science ®Google Scholar
• PauwelsR. Global initiative for chronic obstructive lung diseases (GOLD), time to act. Eur Respir J. 2001;18(6):901–902. doi:10.1183/09031936.01.002740111829093
   PubMed Web of Science ®Google Scholar
• TashkinDP, FergusonGT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res. 2013;14:49. doi:10.1186/1465-9921-14-4923651244
   PubMed Web of Science ®Google Scholar
• DahlR, GreefhorstLA, NowakD, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(5):778–784. doi:10.1164/ajrccm.164.5.200700611549532
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care (Partial Update). London: National Clinical Guideline Centre; 2010 Available from: http://www.nice.org.uk/CG101. Accessed 822, 2019.
   Google Scholar
• The Global Strategy for the Diagnosis, Management and Prevention of COPD. Global initiative for chronic obstructive lung disease. GOLD. 2018 Available from: https://goldcopd.org/archived-reports/. Accessed 822, 2019.
   Google Scholar
• CazzolaM, MolimardM. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23(4):257–267. doi:10.1016/j.pupt.2010.03.00320381630
   PubMed Web of Science ®Google Scholar
• BatemanED, FergusonGT, BarnesN, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy, the SHINE study. Eur Respir J. 2013;42(6):1484–1494. doi:10.1183/09031936.0020021223722616
   PubMed Web of Science ®Google Scholar
• DonohueJF, Maleki-YazdiMR, KilbrideS, MehtaR, KalbergC, ChurchA. Efficacy and safety of once-daily umeclidinium/vilanterol 62. 5/25mcg in COPD. Respir Med. 2013;107(10):1538–1546. doi:10.1016/j.rmed.2013.06.00123830094
   PubMed Web of Science ®Google Scholar
• ToyEL, BeaulieuNU, McHaleJM, et al. Treatment of COPD, relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105(3):435–441. doi:10.1016/j.rmed.2010.09.00620880687
   PubMed Web of Science ®Google Scholar
• van NoordJA, AumannJ-L, JanssensE, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J. 2005;26(2):214–222. doi:10.1183/09031936.05.0014040416055868
   PubMed Web of Science ®Google Scholar
• TashkinDP, PearleJ, IezzoniD, VargheseST. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD. 2009;6(1):17–25. doi:10.1080/1541255090272407319229704
   PubMedGoogle Scholar
• JonesPW, LeidyNK, HareendranA, LamarcaR, ChuecosF, Garcia GilE. The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the evaluating respiratory symptoms in COPD (E-RS, COPD) diary: pooled analysis of two 6-month Phase III studies. Respir Res. 2016;17(1):61. doi:10.1186/s12931-016-0372-127215749
   PubMed Web of Science ®Google Scholar
• KerwinEM, D’UrzoAD, GelbAF, LakkisH, Garcia GilE, CaractaCF. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD. 2012;9(2):90–101. doi:10.3109/15412555.2012.66149222320148
   PubMedGoogle Scholar
• BeierJ, KirstenA-M, MrózR, et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled phase IIIb study. COPD. 2013;10(4):511–522. doi:10.3109/15412555.2013.81462623819698
   PubMedGoogle Scholar
• LeidyNK, WilcoxTK, JonesPW, et al. Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure. Value Health. 2010;13(8):965–975. doi:10.1111/j.1524-4733.2010.00772.x20659270
   PubMed Web of Science ®Google Scholar
• SethiS, KerwinE, WatzH, et al. AMPLIFY, A randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:667–682. doi:10.2147/COPD.S18913830962681
   PubMed Web of Science ®Google Scholar
• JonesPW, HardingG, BerryP, WiklundI, ChenW-H, Kline LeidyN. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34(3):648–654. doi:10.1183/09031936.0010250919720809
   PubMed Web of Science ®Google Scholar
• TashkinDP, CelliB, SennS, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554. doi:10.1056/NEJMoa080580018836213
   PubMed Web of Science ®Google Scholar
• van NoordJA, AumannJ-L, JanssensE, et al. Combining tiotropium and salmeterol in COPD, effects on airflow obstruction and symptoms. Respir Med. 2010;104(7):995–1004. doi:10.1016/j.rmed.2010.02.01720303247
   PubMed Web of Science ®Google Scholar
• VogelmeierCF, BatemanED, PallanteJ, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE), A randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1(1):51–60. doi:10.1016/S2213-2600(12)70052-824321804
   PubMed Web of Science ®Google Scholar
• De la HayeR, HerboldM. Anwendungsbeobachtungen: Leitfaden für die praktische Durchführung [Observational study: Guideline for practical implementation]. German: Verlag ECV Editio Cantor; 2000.
   Google Scholar
• WedzichaJA, SeemungalTAR. COPD exacerbations, defining their cause and prevention. Lancet. 2007;370(9589):786–796. doi:10.1016/S0140-6736(07)61382-817765528
   PubMed Web of Science ®Google Scholar
• SeemungalTA, DonaldsonGC, PaulEA, BestallJC, JeffriesDJ, WedzichaJA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1418–1422. doi:10.1164/ajrccm.157.5.97090329603117
   PubMed Web of Science ®Google Scholar
• HurstJR, WedzichaJA. What is (and what is not) a COPD exacerbation, thoughts from the new GOLD guidelines. Thorax. 2007;62(3):198–199. doi:10.1136/thx.2007.07788317329557
   PubMed Web of Science ®Google Scholar
• BurgeS, WedzichaJA. COPD exacerbations: definitions and classifications. Eur Respir J. Supplement. 2003;41(Supplement 41):46s–53s. doi:10.1183/09031936.03.00078002
   PubMedGoogle Scholar
• JonesPW, BrusselleG, Dal NegroRW, et al. Properties of the COPD assessment test in a cross-sectional European study. Eur Respir J. 2011;38(1):29–35. doi:10.1183/09031936.0017721021565915
   PubMed Web of Science ®Google Scholar
• KesslerR, PartridgeMR, MiravitllesM, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2011;37(2):264–272. doi:10.1183/09031936.0005111021115606
   PubMed Web of Science ®Google Scholar
• PartridgeMR, KarlssonN, SmallIR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin. 2009;25(8):2043–2048. doi:10.1185/0300799090310300619569976
   PubMed Web of Science ®Google Scholar
• PalsgroveA, HoughtonK. The development of the early morning symptoms of COPD instrument (EMSCI). Int J Chron Obstruct Pulmon Dis. 2018;13:1633–1645. doi:10.2147/COPD.S15208729849455
   PubMed Web of Science ®Google Scholar
• ChapmanKR, ManninoDM, SorianoJB, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J. 2006;27(1):188–207. doi:10.1183/09031936.06.0002450516387952
   PubMed Web of Science ®Google Scholar
• WaltersJ. COPD - diagnosis, management and the role of the GP. Aust Fam Physician. 2010;39(3):100–103.20369108
   PubMedGoogle Scholar
• MarthK, SchullerE, PohlW. Improvements in patient-reported outcomes: a prospective, non-interventional study with aclidinium bromide for treatment of COPD. Respir Med. 2015;109(5):616–624. doi:10.1016/j.rmed.2015.02.00425796962
   PubMed Web of Science ®Google Scholar
• HalbertRJ, NatoliJL, GanoA, BadamgaravE, BuistAS, ManninoDM. Global burden of COPD, systematic review and meta-analysis. Eur Respir J. 2006;28(3):523–532. doi:10.1183/09031936.06.0012460516611654
   PubMed Web of Science ®Google Scholar
• SalviSS, BarnesPJ. Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009;374(9691):733–743. doi:10.1016/S0140-6736(09)61303-919716966
   PubMed Web of Science ®Google Scholar
• CelliBR, HalbertRJ, NordykeRJ, SchauB. Airway obstruction in never smokers, results from the third National Health and Nutrition Examination Survey. Am J Med. 2005;118(12):1364–1372. doi:10.1016/j.amjmed.2005.06.04116378780
   PubMed Web of Science ®Google Scholar
• MeyerPA, ManninoDM, ReddSC, OlsonDR. Characteristics of adults dying with COPD. Chest. 2002;122(6):2003–2008. doi:10.1378/chest.122.6.200312475839
   PubMed Web of Science ®Google Scholar
• FabbriLM, LuppiF, BeghéB, RabeKF. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31(1):204–212. doi:10.1183/09031936.0011430718166598
   PubMed Web of Science ®Google Scholar
• DivoM, CoteC, de TorresJP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155–161. doi:10.1164/rccm.201201-0034OC22561964
   PubMed Web of Science ®Google Scholar
• SinghD, JonesPW, BatemanED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD), s multicentre, randomised study. BMC Pulm Med. 2014;14:178. doi:10.1186/1471-2466-14-17825404569
   PubMed Web of Science ®Google Scholar
• SinghD, FergusonGT, BolitschekJ, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015;109(10):1312–1319. doi:10.1016/j.rmed.2015.08.00226320402
   PubMed Web of Science ®Google Scholar
• D’UrzoAD, RennardSI, KerwinEM, MergelV, LeselbaumAR, CaractaCF. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate, the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res. 2014;15:123. doi:10.1186/s12931-014-0123-025756831
   PubMed Web of Science ®Google Scholar
• D’UrzoA, RennardS, KerwinE, et al. A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respir Med. 2017;125:39–48. doi:10.1016/j.rmed.2017.02.00828340861
   PubMed Web of Science ®Google Scholar
• BuhlR, MaltaisF, AbrahamsR, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur Respir J. 2015;45(4):969–979. doi:10.1183/09031936.0013601425573406
   PubMed Web of Science ®Google Scholar
• WedzichaJA, DecramerM, FickerJH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK), a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1(3):199–209. doi:10.1016/S2213-2600(13)70052-324429126
   PubMed Web of Science ®Google Scholar
• CalzettaL, RoglianiP, MateraMG, CazzolaM. A Systematic Review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest. 2016;149(5):1181–1196. doi:10.1016/j.chest.2016.02.64626923629
   PubMed Web of Science ®Google Scholar
• MahlerDA, KerwinE, AyersT, et al. FLIGHT1 and FLIGHT2, efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(9):1068–1079. doi:10.1164/rccm.201505-1048OC26177074
   PubMed Web of Science ®Google Scholar
• WorthH, BuhlR, CrieeC-P, KardosP, LossiNS, VogelmeierCF. GOLD 2017 treatment pathways in ‘real life’, an analysis of the DACCORD observational study. Respir Med. 2017;131:77–84. doi:10.1016/j.rmed.2017.08.00828947047
   PubMed Web of Science ®Google Scholar
• BuhlR, CrieeC-P, KardosP, et al. Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study. Int J Chron Obstruct Pulmon Dis. 2018;13:2557–2568. doi:10.2147/COPD.S16995830197512
   PubMed Web of Science ®Google Scholar
• Lopez-GonzalezE, HerdeiroMT, FigueirasA. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009;32(1):19–31. doi:10.2165/00002018-200932010-0000219132802
   PubMed Web of Science ®Google Scholar
• KewKM, MavergamesC, WaltersJAE. Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;10:CD010177.
   PubMed Web of Science ®Google Scholar
• JansatJM, LamarcaR, Garcia GilE, FerrerP. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. Int J Clin Pharmacol Ther. 2009;47(7):460–468. doi:10.5414/CPP4746019640353
   PubMed Web of Science ®Google Scholar
• SentellasS, RamosI, AlbertiJ, et al. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci. 2010;39(5):283–290. doi:10.1016/j.ejps.2010.01.00420093184
   PubMed Web of Science ®Google Scholar
• WiseRA, ChapmanKR, SciricaBM, et al. Effect of aclidinium bromide on major cardiovascular events and exacerbations in high-risk patients with chronic obstructive pulmonary disease, the ASCENT-COPD randomized clinical trial. JAMA. 2019;321(17):1693–1701. doi:10.1001/jama.2019.497331063575
   PubMed Web of Science ®Google Scholar